In a bid to claw back the public health-care costs incurred from the opioid emergency, Canada’s provinces have registered a 67.4-billion US assert against OxyContin manufacturer Purdue Pharma.
In a bid to claw back the public health-care costs incurred from the opioid emergency, Canada’s provinces have registered a 67.4-billion US assert against OxyContin manufacturer Purdue Pharma.
© 2021 Can Press
Theme by Anders Norén — Up ↑